

Bruno Fantin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1391545/publications.pdf>

Version: 2024-02-01

165
papers

6,061
citations

66343

42
h-index

95266

68
g-index

212
all docs

212
docs citations

212
times ranked

6729
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of fluoroquinolone-resistant <i>Escherichia coli</i> in the gut after ciprofloxacin treatment. <i>International Journal of Medical Microbiology</i> , 2022, 312, 151548.	3.6	1
2	Spontaneous and postsurgical/traumatic <i>Klebsiella pneumoniae</i> meningitis: two distinct clinico-microbiological entities. <i>International Journal of Infectious Diseases</i> , 2022, 114, 185-191.	3.3	3
3	Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1773-1777.	2.9	2
4	Early primary toxoplasmosis transmitted by liver graft: A case report. <i>Infectious Diseases Now</i> , 2021, 51, 315-316.	1.6	1
5	Isoniazid-mono-resistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. <i>International Journal of Infectious Diseases</i> , 2021, 107, 86-91.	3.3	11
6	Activity of the combination of colistin and fosfomycin against NDM-1-producing <i>Escherichia coli</i> with variable levels of susceptibility to colistin and fosfomycin in a murine model of peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 155-163.	3.0	3
7	More complications in cervical than in non-cervical spine tuberculosis. <i>Infectious Diseases</i> , 2020, 52, 170-176.	2.8	5
8	Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in <i>Escherichia coli</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 575031.	3.5	10
9	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. <i>Annals of Medicine</i> , 2020, 52, 367-375.	3.8	28
10	Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of <i>Escherichia coli</i> producing or not producing a metallo- β -lactamase in vitro and in murine peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3593-3600.	3.0	5
11	Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. <i>Journal of Infection</i> , 2020, 81, e4-e6.	3.3	767
12	Mortality in <i>Escherichia coli</i> bloodstream infections: antibiotic resistance still does not make it. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2334-2343.	3.0	41
13	Different kinetics of infectious processes in vertebral osteomyelitis of pyogenic or tuberculous origin explain different timing of surgery. <i>Infectious Diseases</i> , 2020, 52, 563-570.	2.8	0
14	Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing <i>Escherichia coli</i> in a Murine Model of Lethal Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
15	Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19. <i>Journal of Infection</i> , 2020, 81, e96-e98.	3.3	53
16	Pyogenic liver abscess in liver transplant recipient: A warning signal for the risk of recurrence and retransplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13360.	1.7	6
17	Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial. <i>Microorganisms</i> , 2020, 8, 941.	3.6	21
18	Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against <i>Escherichia coli</i> in a high-inoculum murine peritonitis model. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1416.e5-1416.e9.	6.0	5

#	ARTICLE	IF	CITATIONS
19	Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1247.	4.1	16
20	Management of acute community-acquired bacterial meningitis (excluding newborns). Short text. <i>MÃ©decine Et Maladies Infectieuses</i> , 2019, 49, 367-398.	5.0	17
21	Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies. <i>MÃ©decine Et Maladies Infectieuses</i> , 2019, 49, 296-317.	5.0	17
22	The inoculum effect of <i>Escherichia coli</i> expressing <i>mcr-1</i> or not on colistin activity in a murine model of peritonitis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1563.e5-1563.e8.	6.0	7
23	Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing <i>Escherichia coli</i> clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1323-1326.	3.0	6
24	Acute cholangitis: Diagnosis and management. <i>Journal of Visceral Surgery</i> , 2019, 156, 515-525.	0.8	52
25	Unexpected Activity of Oral Fosfomycin against Resistant Strains of <i>Escherichia coli</i> in Murine Pyelonephritis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
26	Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. <i>MÃ©decine Et Maladies Infectieuses</i> , 2019, 49, 335-346.	5.0	41
27	Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosis. <i>MÃ©decine Et Maladies Infectieuses</i> , 2019, 49, 318-334.	5.0	55
28	Monoclonal gammopathies and hypergammaglobulemia in Gaucher disease: An analysis from the French Gaucher disease registry. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S107.	1.1	0
29	Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study. <i>Travel Medicine and Infectious Disease</i> , 2019, 29, 40-47.	3.0	5
30	A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. <i>Clinical Microbiology and Infection</i> , 2019, 25, 830-838.	6.0	106
31	Surgery is safe and effective when indicated in the acute phase of hematogenous pyogenic vertebral osteomyelitis. <i>Infectious Diseases</i> , 2019, 51, 268-276.	2.8	9
32	Angiocholites: diagnostic et prise en charge. <i>Journal De Chirurgie ViscÃ©rale</i> , 2019, 156, 552-563.	0.0	1
33	Prediction of the intestinal resistome by a three-dimensional structure-based method. <i>Nature Microbiology</i> , 2019, 4, 112-123.	13.3	129
34	Flagellate erythema in systemic sclerosis: A case report. <i>JAAD Case Reports</i> , 2018, 4, 239-241.	0.8	2
35	Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 417-421.	2.9	23
36	Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective Study. <i>American Journal of Medicine</i> , 2018, 131, 319-322.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and Pharmacodynamics of Temocillin. <i>Clinical Pharmacokinetics</i> , 2018, 57, 287-296.	3.5	42
38	Hypervirulent <i>Klebsiella pneumoniae</i> in Cryptogenic Liver Abscesses, Paris, France. <i>Emerging Infectious Diseases</i> , 2018, 24, 221-229.	4.3	47
39	Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3074-3080.	3.0	18
40	Increased mortality in patients aged 75 years or over with pyogenic vertebral osteomyelitis. <i>Infectious Diseases</i> , 2018, 50, 783-787.	2.8	3
41	Faecal microbiota transplantation with frozen capsules for relapsing <i>Clostridium difficile</i> infections: the first experience from 15 consecutive patients in France. <i>Journal of Hospital Infection</i> , 2018, 100, 148-151.	2.9	13
42	An outbreak of <i>Pneumocystis jirovecii</i> pneumonia among liver transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12956.	1.7	11
43	Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1574-1580.	3.0	19
44	Characteristics of and risk factors for severe neurological deficit in patients with pyogenic vertebral osteomyelitis. <i>Medicine (United States)</i> , 2017, 96, e6387.	1.0	50
45	Management of adult infectious encephalitis in metropolitan France. <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 206-220.	5.0	7
46	Biological cost of fosfomycin resistance in <i>Escherichia coli</i> in a murine model of urinary tract infection. <i>International Journal of Medical Microbiology</i> , 2017, 307, 452-459.	3.6	18
47	Cytomegalovirus-associated protein-losing enteropathy in a healthy man. <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 562-565.	5.0	6
48	Autochthonous Case of Eosinophilic Meningitis Caused by <i>Angiostrongylus cantonensis</i> , France, 2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 1045-1046.	4.3	28
49	Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1899-1904.	3.0	22
50	Presentation and impact of catheter-associated thrombosis in patients with infected long-term central venous catheters: a prospective bicentric observational study. <i>Annals of Medicine</i> , 2016, 48, 182-189.	3.8	6
51	Prospective Cohort Study of the Relative Abundance of Extended-Spectrum-Beta-Lactamase-Producing <i>Escherichia coli</i> in the Gut of Patients Admitted to Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6941-6944.	3.2	8
52	Medical complications following splenectomy. <i>Journal of Visceral Surgery</i> , 2016, 153, 277-286.	0.8	86
53	<i>qnrA6</i> genetic environment and quinolone resistance conferred on <i>Proteus mirabilis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 903-908.	3.0	4
54	Costs associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France. <i>BMJ Open</i> , 2016, 6, e009029.	1.9	26

#	ARTICLE	IF	CITATIONS
55	Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> in a Murine Model of Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 424-430.	3.2	10
56	Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 653-659.	2.5	18
57	Characteristics of vertebral osteomyelitis after liver transplantation. <i>Clinical Microbiology and Infection</i> , 2015, 21, 573-577.	6.0	3
58	Activity of temocillin in a murine model of urinary tract infection due to <i>Escherichia coli</i> producing or not producing the ESBL CTX-M-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1466-1472.	3.0	29
59	Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. <i>Future Microbiology</i> , 2015, 10, 1241-1255.	2.0	41
60	Invasive actinomycosis: surrogate marker of a poor prognosis in immunocompromised patients. <i>International Journal of Infectious Diseases</i> , 2014, 29, 74-79.	3.3	21
61	Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3393-3400.	3.0	45
62	Behcet's disease in Budd-Chiari syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 104.	2.7	57
63	<i>Escherichia coli</i> bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. <i>Epidemiology and Infection</i> , 2014, 142, 2672-2683.	2.1	18
64	Quinolone-resistant <i>Escherichia coli</i> from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 761-768.	3.0	16
65	Activity of fosfomycin alone or combined with ceftiofuran in vitro and in vivo in a murine model of urinary tract infection due to <i>Escherichia coli</i> harbouring CTX-M-15-type extended-spectrum β -lactamase. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 366-369.	2.5	16
66	Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic-Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2013, 52, 869-883.	3.5	16
67	Resolution of <i>Clostridium difficile</i> -Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. <i>Journal of Clinical Oncology</i> , 2013, 31, 2493-2499.	1.6	93
68	Ciprofloxacin Treatment Failure in a Murine Model of Pyelonephritis Due to an AAC(6)-Ib-cr-Producing <i>Escherichia coli</i> Strain Susceptible to Ciprofloxacin <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5830-5835.	3.2	34
69	Ceftiofuran as an Alternative to Carbapenems in a Murine Model of Urinary Tract Infection Due to <i>Escherichia coli</i> Harboring CTX-M-15-Type Extended-Spectrum β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1376-1381.	3.2	41
70	Diversity of Individual Dynamic Patterns of Emergence of Resistance to Quinolones in <i>Escherichia coli</i> From the Fecal Flora of Healthy Volunteers Exposed to Ciprofloxacin. <i>Journal of Infectious Diseases</i> , 2012, 206, 1399-1406.	4.0	31
71	Three-Month Antibiotic Therapy for Early-Onset Postoperative Spinal Implant Infections. <i>Clinical Infectious Diseases</i> , 2012, 55, 1481-1487.	5.8	45
72	<i>Salmonella</i> Colindale osteomyelitis in an immunocompetent female patient. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 36-37.	5.0	2

#	ARTICLE	IF	CITATIONS
73	Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 53-57.	1.4	35
74	The French Gaucherâ€™s disease registry: clinical characteristics, complications and treatment of 562 patients. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 77.	2.7	97
75	Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 319-325.	2.9	33
76	Do Case Vignettes Accurately Reflect Antibiotic Prescription?. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 1003-1009.	1.8	19
77	Tuberculous cerebral vasculitis: Retrospective study of 10 cases. <i>European Journal of Internal Medicine</i> , 2011, 22, e99-e104.	2.2	20
78	Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 34-38.	1.4	19
79	Bacteraemia caused by third-generation cephalosporin-resistant <i>Escherichia coli</i> in France: prevalence, molecular epidemiology and clinical features. <i>Clinical Microbiology and Infection</i> , 2011, 17, 557-565.	6.0	65
80	Differences in daptomycin and vancomycin ex vivo behaviour can lead to false interpretation of negative blood cultures. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1264-1267.	6.0	1
81	Physicians fail to consider <i>Pseudomonas aeruginosa</i> as a potential pathogen in medicine patients with bacteremia. <i>Journal of Infection</i> , 2011, 63, 99-101.	3.3	3
82	Arthrite septique destructrice Ã <i>Ureaplasma urealyticum</i> aprÃs un traitement par rituximab chez un patient atteint de lupus ÃrythÃmateux systÃmique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, 296-297.	0.0	0
83	Antibiotic use: knowledge and perceptions in two university hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 936-940.	3.0	29
84	Flow Cytometry as a Tool To Determine the Effects of Cell Wall-Active Antibiotics on Vancomycin-Susceptible and -Resistant <i>Enterococcus faecalis</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 395-398.	3.2	11
85	The <i>In Vitro</i> Contribution of Autolysins to Bacterial Killing Elicited by Amoxicillin Increases with Inoculum Size in <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 910-912.	3.2	15
86	Host Factors and Portal of Entry Outweigh Bacterial Determinants To Predict the Severity of <i>Escherichia coli</i> Bacteremia. <i>Journal of Clinical Microbiology</i> , 2011, 49, 777-783.	3.9	123
87	Plasmidic qnrA3 Enhances <i>Escherichia coli</i> Fitness in Absence of Antibiotic Exposure. <i>PLoS ONE</i> , 2011, 6, e24552.	2.5	26
88	Broad-Range 16S rRNA PCR with Cerebrospinal Fluid May Be Unreliable for Management of Postoperative Aseptic Meningitis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3331-3333.	3.9	11
89	Independent Behavior of Commensal Flora for Carriage of Fluoroquinolone-Resistant Bacteria in Patients at Admission. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5193-5200.	3.2	27
90	Reduced Antibiotic Pressure for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Back to the Future. <i>Clinical Infectious Diseases</i> , 2010, 51, 150-152.	5.8	12

#	ARTICLE	IF	CITATIONS
91	R�sistance aux fluoroquinolones en 2010�: quel impact pour la prescription en r�animation�?. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2010, 19, 347-353.	0.1	7
92	Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria. Journal of Infectious Diseases, 2009, 200, 390-398.	4.0	105
93	Contribution of the Autolysin AtlA to the Bactericidal Activity of Amoxicillin against Enterococcus faecalis JH2-2. Antimicrobial Agents and Chemotherapy, 2009, 53, 1667-1669.	3.2	10
94	Impact of Low-Level Resistance to Fluoroquinolones Due to <i>qnrA1</i> and <i>qnrS1</i> Genes or a <i>gyrA</i> Mutation on Ciprofloxacin Bactericidal Activity in a Murine Model of <i>Escherichia coli</i> Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 4292-4297.	3.2	71
95	Bactericidal Activity of the Combination of Levofloxacin with Rifampin in Experimental Prosthetic Knee Infection in Rabbits Due to Methicillin-Susceptible <i>Staphylococcus aureus</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 2145-2148.	3.2	15
96	Risk factors for <i>Enterobacteriaceae</i> bacteremia after liver transplantation. Transplant International, 2008, 21, 755-763.	1.6	43
97	Actualit�s sur la prise en charge des abc�s c�r�braux de l�adulte. Antibiotiques, 2008, 10, 106-114.	0.1	1
98	Technetium 99m�Labeled Annexin V Scintigraphy of Platelet Activation in Vegetations of Experimental Endocarditis. Circulation, 2008, 117, 781-789.	1.6	39
99	Accuracy and Potential Usefulness of Triplex Real-Time PCR for Improving Antibiotic Treatment of Patients with Blood Cultures Showing Clustered Gram-Positive Cocci on Direct Smears. Journal of Clinical Microbiology, 2008, 46, 2045-2051.	3.9	52
100	Evaluation of the Management of Postoperative Aseptic Meningitis. Clinical Infectious Diseases, 2007, 44, 1555-1559.	5.8	86
101	Amoxicillin Is Effective against Penicillin-Resistant <i>Streptococcus pneumoniae</i> Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2007, 51, 208-214.	3.2	18
102	Risk Factors for <i>Clostridium difficile</i> Infection in a Hepatology Ward. Infection Control and Hospital Epidemiology, 2007, 28, 202-204.	1.8	23
103	Polyvalent 23 epitope polysaccharide pneumonia vaccine induced effective protection through strain-adapted effector mechanisms as demonstrated by the different cytokine responses in mice challenged with two different strains of <i>Streptococcus pneumoniae</i> . European Cytokine Network, 2007, 18, 23-30.	2.0	0
104	Mod�les exp�rimentaux�: quels�mod�les peuvent encore apporter des�informations dans�le�traitement des�infections bact�riennes�?. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2006, 15, 214-220.	0.1	0
105	Schnitzler�s syndrome: 3-year radiological follow-up. Skeletal Radiology, 2006, 36, 153-156.	2.0	9
106	Spinal Tuberculosis: A Longitudinal Study with Clinical, Laboratory, and Imaging Outcomes. Seminars in Arthritis and Rheumatism, 2006, 36, 124-129.	3.4	45
107	Acquired Gentamicin Resistance by Permeability Impairment in <i>Enterococcus faecalis</i> . Antimicrobial Agents and Chemotherapy, 2006, 50, 3615-3621.	3.2	41
108	Efficacy of Cethromycin, a New Ketolide, against <i>Streptococcus pneumoniae</i> Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2006, 50, 3033-3038.	3.2	15

#	ARTICLE	IF	CITATIONS
109	Imaging does not predict the clinical outcome of bacterial vertebral osteomyelitis. <i>Rheumatology</i> , 2006, 46, 292-295.	1.9	84
110	Bone involvement in generalized crystal-storing histiocytosis. <i>Journal of Rheumatology</i> , 2006, 33, 2354-8.	2.0	3
111	Mutator phenotype confers advantage in <i>Escherichia coli</i> chronic urinary tract infection pathogenesis. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 44, 317-321.	2.7	71
112	Comparative study of postoperative and spontaneous pyogenic spondylodiscitis. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 34, 766-771.	3.4	80
113	Activity of Gemifloxacin against Quinolone-Resistant <i>Streptococcus pneumoniae</i> Strains In Vitro and in a Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1046-1054.	3.2	19
114	Relationship between the Level of Acquired Resistance to Gentamicin and Synergism with Amoxicillin in <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4144-4148.	3.2	14
115	Activities of Garenoxacin against Quinolone-Resistant <i>Streptococcus pneumoniae</i> Strains In Vitro and in a Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 765-773.	3.2	12
116	Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to <i>Staphylococcus aureus</i> with or without Reduced Susceptibility to Vancomycin and Teicoplanin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1061-1064.	3.2	61
117	Expression of Glycopeptide Resistance Gene in Response to Vancomycin and Teicoplanin in the Cardiac Vegetations of Rabbits Infected with VanB Type <i>Enterococcus faecalis</i> . <i>Journal of Infectious Diseases</i> , 2004, 189, 90-97.	4.0	13
118	De la colonie microbienne à l'infection chez l'homme : le cas de <i>Pseudomonas aeruginosa</i> , importance thérapeutique. <i>Antibiotiques</i> , 2004, 6, 241-248.	0.1	0
119	Acute pulmonary embolism. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1241-1244.	1.6	16
120	Cervical involvement in SAPHO syndrome: imaging findings with a 10-year follow-up. <i>Skeletal Radiology</i> , 2003, 32, 103-106.	2.0	12
121	Recurrent valvular replacement due to exacerbation of Behçet's disease by <i>Streptococcus agalactiae</i> infection. <i>European Journal of Internal Medicine</i> , 2003, 14, 120-122.	2.2	9
122	Hypoparathyroidism preceding Riedel's thyroiditis. <i>European Journal of Internal Medicine</i> , 2003, 14, 202-204.	2.2	6
123	Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 216-222.	3.2	67
124	Influence of Reduced Susceptibility to Glycopeptides on Activities of Vancomycin and Teicoplanin against <i>Staphylococcus aureus</i> in Experimental Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2018-2021.	3.2	18
125	Influence of VanD Type Resistance on Activities of Glycopeptides In Vitro and in Experimental Endocarditis Due to <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3515-3518.	3.2	4
126	Efficacies of Quinupristin-Dalfopristin Combined with Vancomycin In Vitro and in Experimental Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> in Relation to Cross-Resistance to Macrolides, Lincosamides, and Streptogramin B-Type Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3061-3064.	3.2	28

#	ARTICLE	IF	CITATIONS
127	Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2200-2207.	3.2	84
128	Acute respiratory failure due to diaphragmatic weakness revealing a polymyositis. <i>European Journal of Internal Medicine</i> , 2002, 13, 203-205.	2.2	9
129	Consequences of VanE-Type Resistance on Efficacy of Glycopeptides In Vitro and in Experimental Endocarditis Due to <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2826-2830.	3.2	6
130	Clinical Evaluation of the Management of Community-Acquired Pneumonia by General Practitioners in France. <i>Chest</i> , 2001, 120, 185-192.	0.8	36
131	Activities of the Combination of Quinupristin-Dalfopristin with Rifampin In Vitro and in Experimental Endocarditis Due to <i>Staphylococcus aureus</i> Strains with Various Phenotypes of Resistance to Macrolide-Lincosamide-Streptogramin Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1244-1248.	3.2	31
132	Activity of LY333328 Combined with Gentamicin In Vitro and in Rabbit Experimental Endocarditis Due to Vancomycin-Susceptible or -Resistant <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3017-3021.	3.2	57
133	Bactericidal Activity of Gentamicin against <i>Enterococcus faecalis</i> In Vitro and In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2077-2080.	3.2	17
134	Association between Nasal Carriage of <i>Staphylococcus Aureus</i> and Infection in Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2000, 31, 1295-1299.	5.8	67
135	Influence of Resistance to Streptogramin A Type Antibiotics on the Activity of Quinupristin-Dalfopristin In Vitro and in Experimental Endocarditis Due to <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1168-1173.	3.2	21
136	Two-Step Acquisition of Resistance to the Teicoplanin-Gentamicin Combination by VanB-Type <i>Enterococcus faecalis</i> In Vitro and in Experimental Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 476-482.	3.2	27
137	Activity and Diffusion of LY333328 in Experimental Endocarditis Due to Vancomycin-Resistant <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 115-120.	3.2	60
138	Pression de sélection des antibiotiques: données expérimentales. <i>Reanimation Urgences</i> , 1999, 8, 1s-4s.	0.1	0
139	Critical Importance of In Vivo Amoxicillin and Cefotaxime Concentrations for Synergy in Treatment of Experimental <i>Enterococcus faecalis</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 468-470.	3.2	14
140	Multifocal osteonecrosis after chemotherapy in a patient with breast cancer. <i>Journal of Rheumatology</i> , 1998, 25, 2479-80.	2.0	3
141	Selection of Glycopeptide-Resistant Mutants of VanB-Type <i>Enterococcus faecalis</i> BM4281 In Vitro and in Experimental Endocarditis. <i>Journal of Infectious Diseases</i> , 1997, 175, 598-605.	4.0	67
142	Contribution of animal models of infection for the evaluation of the activity of antimicrobial agents. <i>International Journal of Antimicrobial Agents</i> , 1997, 9, 73-82.	2.5	10
143	Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in <i>Enterococcus faecium</i> on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 931-935.	3.2	53
144	Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 1219-1224.	3.2	16

#	ARTICLE	IF	CITATIONS
145	Lymphocyte Subset Counts During the Course of Community-Acquired Pneumonia: Evolution According to Age, Human Immunodeficiency Virus Status, and Etiologic Microorganisms. <i>Clinical Infectious Diseases</i> , 1996, 22, 1096-1098.	5.8	38
146	Vancomycine (Vm) et teicoplanine (Te) dans l'endocardite expérimentale du lapin due à de phénotype vanB : activité et sélection de variants résistants. <i>Médecine Et Maladies Infectieuses</i> , 1996, 26, 882-883.	5.0	0
147	Critical influence of timing of administration of granulocyte colony-stimulating factor on antibacterial effect in experimental endocarditis due to <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 2702-2707.	3.2	6
148	Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 400-405.	3.2	97
149	Conditions for the emergence of resistance to ceftiofime and ceftazidime in experimental endocarditis due to <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 563-569.	3.0	66
150	Influence of antimicrobial therapy on kinetics of tumor necrosis factor levels in experimental endocarditis caused by <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 1017-1022.	3.2	14
151	In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 432-437.	3.2	51
152	Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 2466-2469.	3.2	29
153	Pharmacokinetic and pharmacodynamic aspects of therapy of experimental endocarditis. <i>Infectious Disease Clinics of North America</i> , 1993, 7, 37-51.	5.1	5
154	In vivo antibiotic synergism: contribution of animal models. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 907-912.	3.2	121
155	Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 1413-1422.	3.2	89
156	Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of <i>Serratia marcescens</i> endocarditis: in vitro-in vivo correlation. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 111-116.	3.2	25
157	Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 27, 829-836.	3.0	92
158	Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 2085-2090.	3.2	32
159	Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 1570-1575.	3.2	53
160	Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by <i>Escherichia coli</i> producing SHV-2-like beta-lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 581-586.	3.2	53
161	Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of <i>Enterococcus faecalis</i> -induced experimental endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 2387-2391.	3.2	74
162	Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. <i>Scandinavian Journal of Infectious Diseases, Supplement</i> , 1990, 74, 179-84.	0.3	55

#	ARTICLE	IF	CITATIONS
163	Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection Models. <i>Journal of Infectious Diseases</i> , 1989, 159, 281-292.	4.0	357
164	Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental <i>Escherichia coli</i> endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 767-770.	3.2	42
165	Infections sur materiel d'osteosynthese. <i>Médecine Et Maladies Infectieuses</i> , 1987, 17, 357.	5.0	0